Neoplasms of the brain and spinal cord are tumors which can form in one or more regions of the central nervous system. These tumors can originate from the brain or the spinal cord depending on the type of neoplasm. Neoplasms of the brain and spinal cord have the potential to cause a variety of symptoms depending on their location and size. The most common neoplasms of the brain and spinal cord are classified as either primary or metastatic. Primary neoplasms are tumors that originate in the brain or spinal cord, while metastatic tumors spread to those regions from a primary source elsewhere in the body. Primary brain neoplasms can be grouped into four major categories: gliomas, meningiomas, vestibular schwannomas, and pituitary adenomas. Metastatic neoplasms are typically caused by carcinomas from other parts of the body. Neoplasms of the brain and spinal cord can be benign or malignant. Benign tumors tend to grow slowly and rarely metastasize, whereas malignant tumors can grow more quickly and spread to other regions of the body. Symptoms associated with these neoplasms vary depending on the type, size and location of the tumor. Common signs and symptoms of a brain or spinal cord tumor include headaches, seizures, nausea, vomiting, and changes in mental status. Medical imaging of the brain and spinal cord is essential for diagnosing tumors or neoplasms. MRI and CT scans are the most sensitive techniques for detecting neoplasms of these regions. A biopsy may also be required for confirming the diagnosis and helping to clarify the tumor grade. Treatment for neoplasms of the brain and spinal cord depends on the type, size and location of the tumor. Surgery is typically the most common treatment, and may involve the removal of the entire or a portion of the tumor. Radiotherapy and chemotherapy may also be required in certain circumstances.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States